A newly discovered gene combined with an already known genetic factor could explain the risk of skin side effects in more ...
A newly identified genetic marker may significantly improve the ability to predict life-threatening reactions to the gout ...
A recent study discovered that a new gene test may assist predict which gout patients could suffer dangerous skin reactions ...
Gout flare in the hand of an elderly person Researchers evaluated the efficacy and safety of anakinra for the treatment of acute gout flares. Undergoing 5 days of therapy with the IL-1 receptor ...
October 2, 2012 — New gout guidelines from the American College of Rheumatology are meant to improve gout management by providing clinicians with clear, readily implemented guidance on urate-lowering ...
When you think of arthritis, achy, warm, swollen joints probably come to mind. These are indeed some of the most common symptoms of arthritis. But did you know there are actually over 100 different ...
Atom’s lingdolinurad (ABP-671), a URAT1 inhibitor, is in late stage global clinical trials for chronic gout and ABP-745, an anti-inflammatory drug, is in multi-country Phase 2 trials for acute gout ...
Results of a Phase 2a dose escalating study of lingdolinurad (ABP-671) for chronic gout, which enrolled patients with mild to moderate renal impairment, showed the URAT1 inhibitor lowered serum uric ...
The drug colchicine may reduce cardiovascular outcomes among patients with gout, based on a range of retrospective data that ...
Atom Therapeutics, a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, announced today it has enrolled the first patient in a ...
Each month, Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Each year there are 3.9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback